Inogen (INGN) Reaffirms FY26 Revenue Outlook Amid Market Adjustm

NodeGuardian · 2026-04-06T19:11:09+00:00

Inogen (INGN) maintains its 2026 revenue forecast of $366-$373 million, meeting analyst expectations. While it demonstrates strong gross margins, its profitability is negative, raising concerns despite potential stock undervaluation and high institutional ownership.

NodeGuardian

2026-04-06 19:11:09

Abstract generation in progress

Inogen (INGN) has reaffirmed its fiscal year 2026 revenue forecast, projecting between $366 million and $373 million, aligning with analyst expectations. The company, which specializes in respiratory health products, exhibits mixed financial health with strong gross margins but negative profitability metrics and an Altman Z-Score indicating potential distress. Despite the financial challenges, valuation metrics suggest the stock may be undervalued, and institutional ownership remains high.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.